CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response
Nucleic Acids Research · 2025
DOI: 10.1093/nar/gkaf1363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Gianna Stella und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Bacteriology, The Rockefeller University, New York, NY 10065, United States. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Phosphoric Monoester Hydrolases, CRISPR-Associated Proteins, Bacterial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas (CRISPR-associated) systems provide adaptive immunity against phage infection in prokaryotes using an RNA-guided complex that recognizes complementary foreign nucleic acids. Different types of CRISPR–Cas systems have been identified that differ in their mechanism of defense. Upon infection, type III CRISPR–Cas systems employ the Cas10 complex to find phage transcripts and synthesize cyclic oligo-adenylate (cOA) messengers. These ligands bind and activate CARF immune effectors that cause cell toxicity to prevent the completion of the viral lytic cycle. Here, we investigated two proteins containing an N-terminal haloacid dehalogenase (HAD) phosphatase domain followed by four predicted transmembrane helices and a C-terminal CARF domain. We named these proteins Chp for CRISPR-associated HAD phosphatase. We show that, in vivo, Chp localizes to the bacterial membrane and that its activation induces a growth arrest, leads to a depletion of ATP and IMP, and prevents phage propagation during the type III CRISPR–Cas response. In vitro, the CARF domain of Chp binds cyclic tetra-adenylates and the HAD phosphatase domain dephosphorylates dATP, ATP, and IMP. Our findings extend the range of molecular mechanisms employed by CARF effectors to defend prokaryotes against phage infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Bacteriology, The Rockefeller University, New York, NY 10065, United States.
- Tri-Institutional PhD Program in Chemical Biology, Weill Cornell Medical College, Rockefeller University and Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
- Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, New York, NY 10065, United States.
- Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, United States.
ORCID-Profile: Luciano Marraffini
Förderung
- NIH HHS
- NIGMS NIH HHS
- Howard Hughes Medical Institute
- NIH
- HHMI
Zitieren
APA
Stella, G., Ye, L., Brady, S. F., & Marraffini, L. (2025). CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1363
Vancouver
Stella G, Ye L, Brady SF, Marraffini L. CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf1363
BibTeX
@article{Stella2025,
author = {Stella, Gianna and Ye, Linzhi and Brady, Sean F and Marraffini, Luciano},
title = {CARF-HAD phosphatase effectors provide immunity during the type III-A CRISPR–Cas response},
journal = {Nucleic Acids Research},
year = {2025},
doi = {10.1093/nar/gkaf1363}
}
EUVIMED